Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-457-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees122
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable
Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions
What is Allogene Therapeutics' stock symbol?
Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."
How were Allogene Therapeutics' earnings last quarter?
Allogene Therapeutics Inc (NASDAQ:ALLO) released its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.04. View Allogene Therapeutics' Earnings History.
When is Allogene Therapeutics' next earnings date?
What price target have analysts set for ALLO?
12 analysts have issued twelve-month target prices for Allogene Therapeutics' shares. Their forecasts range from $26.00 to $50.00. On average, they anticipate Allogene Therapeutics' share price to reach $36.33 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price. View Analyst Price Targets for Allogene Therapeutics.
What is the consensus analysts' recommendation for Allogene Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allogene Therapeutics.
What are Wall Street analysts saying about Allogene Therapeutics stock?
Here are some recent quotes from research analysts about Allogene Therapeutics stock:
- 1. According to Zacks Investment Research, "Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California. " (8/12/2019)
- 2. William Blair analysts commented, "Allogene Therapeutics, Inc. Just as We are initiating coverage on Outperform rating and $37 fair value estimate. As noted in our sector landscape piece, “Off the The Next Step for Cell Therapy,” we believe that the next phase of growth in the widespread utilization of cell therapies will be catalyzed by the successful development of “off the shelf” modalities. We therefore view Allogene as a core holding for investors looking for exposure to innovation in this subsector with de- risked initial targets and indications." (3/13/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Allogenes’s first earnings call as a public company was fairly uneventful. The company announced detailed information on the Phase 1 trial design for ALLO 501 that was more or less in line with our expectations. Bigger picture, we believe that ALLO is well positioned in the allogeneic CAR T space and that these approaches may be the next chapter in the evolution of CAR T therapies, opening up this modality to a wider patient population. That said, after a strong post-IPO run, we remain on the sidelines given the early stage of ALLO’s proprietary programs and few value inflecting catalysts anticipated before 2020." (3/11/2019)
- 4. Cowen Inc analysts commented, "Tuesday, Synlogic reported 4Q results and reviewed recent progress. Management reiterated plans to present topline results from ongoing Phase 1/2 trials of by mid-year, which could establish POC in patients with hyperammonemia and phenylketonuria (PKU), respectively. While these trials utilize bacterial slurry formulations, management indicated future trials would use pill-based formulations. While the transition may require clinical bridging studies, we view the new formulations as essential for commercial viability. If the SYNB1020 demonstrates a meaningful impact on serum ammonia, next steps could include a trial in urea cycle disorders (UCD), an indication with an established biomarker-based registrational endpoint. With $123M in cash, we believe Synlogic has adequate resources to sustain operations through 2020. $15 PT." (3/8/2019)
Has Allogene Therapeutics been receiving favorable news coverage?
Media headlines about ALLO stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allogene Therapeutics earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Allogene Therapeutics.
Are investors shorting Allogene Therapeutics?
Allogene Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 12,830,000 shares, an increase of 9.6% from the December 31st total of 11,710,000 shares. Based on an average trading volume of 538,500 shares, the short-interest ratio is currently 23.8 days. Approximately 26.2% of the company's shares are short sold. View Allogene Therapeutics' Current Options Chain.
Who are some of Allogene Therapeutics' key competitors?
Some companies that are related to Allogene Therapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of Allogene Therapeutics own?
Who are Allogene Therapeutics' key executives?
Allogene Therapeutics' management team includes the folowing people:
- Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)
- Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)
- Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)
- Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)
- Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52)
When did Allogene Therapeutics IPO?
(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.
Who are Allogene Therapeutics' major shareholders?
Allogene Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include VV Manager LLC (2.37%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang and Group Holdings (Sbs) Advis Tpg. View Institutional Ownership Trends for Allogene Therapeutics.
Which major investors are selling Allogene Therapeutics stock?
ALLO stock was sold by a variety of institutional investors in the last quarter, including VV Manager LLC. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore and Group Holdings (Sbs) Advis Tpg. View Insider Buying and Selling for Allogene Therapeutics.
How do I buy shares of Allogene Therapeutics?
Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Allogene Therapeutics' stock price today?
One share of ALLO stock can currently be purchased for approximately $23.41.
How big of a company is Allogene Therapeutics?
Allogene Therapeutics has a market capitalization of $2.85 billion. The company earns $-211,510,000.00 in net income (profit) each year or ($6.58) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.View Additional Information About Allogene Therapeutics.
What is Allogene Therapeutics' official website?
How can I contact Allogene Therapeutics?
Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]
MarketBeat Community Rating for Allogene Therapeutics (NASDAQ ALLO)
MarketBeat's community ratings are surveys of what our community members think about Allogene Therapeutics and other stocks. Vote "Outperform" if you believe ALLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
